



EWOC-1/ ENGOT-OV23/ GINECO-OV122



Trial setting: Ovarian Cancer

Sponsor :Hospices Civils LYON for


GINECO


Planned No. of patients: 240

Current accrual: – 120

randomized (386 included)

(Randomization stopped since
28/04/2017 for the interim
analysis)





Groups	Countries	Planned sites	Open sites	Active sites	Inclusions	Randomised Patients
MITO	Italy	14	6	5	21	9
NSGO	Sweden	1	1	1	1	0
	Denmark	4	4	1	1	1
	Finland	2	2	1	2	2
CHUM- Montréal	Canada	1	1	1	1	0
GINECO	France	51	49	39	360	108
TOTAL		73	63	48	386	120

Other important information:

Interim analysis timelines

- 20/09/2017 : Cut-off date
- 02/10/2017 : All data entered
- 27/10/2017 : All data monitored
- Near 23/01/2018 : IDMC meeting

During the randomization suspension:

- Inclusions are still possible
- Patients could sign the GVS consent to be screened
- GVS \geq 3 Patients have to be registered in the registry